Microarray study of gene expression in uterine leiomyoma

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 106-111

  Litovkin, K V ^a   Ivanova, O V ^a   Bauer, A ^b   Hoheisel, J D ^b   Bubnov, V V ^a   Zaporozhan, V N ^a  

^a ODESSA NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Gene expression; Microarray; Uterine leiomyoma

Indexed keywords

ARTICLE; CCND1 GENE; CDKN1A GENE; CLDN1 GENE; CONTROLLED STUDY; CRABP2 GENE; DISEASE MARKER; DNA MICROARRAY; FEMALE; FGF7 GENE; FN1 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HNRPM GENE; HUMAN; HUMAN TISSUE; ISOC1 GENE; MAGEC1 GENE; MAPK12 GENE; MOLECULAR PROBE; PATHOGENESIS; PHENOTYPE; PROGNOSIS; RFC GENE; SOX4 GENE; TIE1 GENE; TNFRSF21 GENE; UPREGULATION; UTERUS MYOMA;

DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEIOMYOMA; MYOMETRIUM; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; UTERINE NEOPLASMS;

EID: 46749100227     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine lciomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-7.
2. Kawaguchi K, Fuji S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstct Gynecol 1989; 160:637-41.
3. Slewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107:917-21.
4. Sozn I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin North Am 2006; 33: 41-58.
5. Hsieh YY, Chang CC,Tsai CH, et al. Interleukin (IL)-12 receptor beta 1 codon 378 G homozygote and allele, but not IL-I (beta-511 promoter, 3953 exon 5, receptor antagonist), 1L-2 114, 1L-4-590 intron 3, 1L-8 3'-UTR 2767, and 1L-18 105, are associated with higher susceptibility to leiomyoma. Fertil Steril 2007; 87: 886-95.
6. Litovkin KV, DomenyukVP, Bubnov VV, Zaporozhan VN. Interleukin-6 - 174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 2007; 29: 295-8.
7. Amant F, Dorfling CM, de Brabanter J, et al. A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstet Gynecol Scand 2004; 83: 234-9.
8. Arslan AA, Gold LI, Mittal K, et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 2005; 20: 852-63.
9. Tsibris JC, Segars J, Coppola D, et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002; 78: 114-21.
10. Ann WS, Kim KW, Bae SM, et al. Targeted cellular process profiling approach for uterine leiomyoma using cDNA microarray, proteomics and gene ontology analysis. Int J Exp Pathol 2003; 84: 267-79.
11. Quade BJ, Wang TY, SornbergerK, et al.. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40: 97-108.
12. Wang H, Mahadevappa M, Yamamoto K, et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril 2003; 80: 266-76.
13. Skubitz KM, Skubitz AP. Differential gene expression in uterine leiomyoma. J Lab Clin Med 2003; 141: 297-308.
14. Chegini N, Verala J, Luo X, et al. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig 2003; 10: 161-71.
15. Vanharanta S, Wortham NC, Laiho P, et al. 7q deletion mapping and expression profiling in uterine fibroids. Oncogene 2005; 24: 6545-54.
16. Wei T, Gciser AG, Qian HR, et al. DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids. BMC Womens Health 2007; 7: 5.
17. Lee EJ, Kong G, Lee SH, et al. Profiling of differentially expressed genes in human uterine leiomyomas. Int J Gynecol Cancer 2005; 15: 146-54.
18. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME) -toward standards for microarray data. Nat Genet 2001; 29: 365-71.
19. Fellenberg K, Hauser NC, Brors B, et al. Microarray data warehouse allowing for inclusion of experiment annotations in statistical analysis. Bioinformatics 2002; 18: 423-33.
20. Fellenberg K, Busold C, Witt O, et al. Systematic interpretation of microarray data using experiment annotations. BMC Genomics 2006; 7: 319.
21. Beissbarth T, Fellenberg K, Brors B, et al. Processing and quality control of DNA array hybridisation data. Bioinformatics 2000; 16: 1014-22.
22. Fellenberg K, Hauser NC, Brors B, et al. Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 2001; 98: 10781-6.
23. Catherino W, Salama A, Potlog-Nahari C, et al. Gene expression studies in leiomyomata: new directions for research. Semin Reprod Med 2004; 22: 83-90.
24. Zaitseva M, Vollenhoven BJ, Rogers PA. Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium. Mol Hum Reprod 2007; 13: 577-85.
25. Kovács KA, Oszter A, Göcze PM, et al. Comparative analysis of cyclin D1 and oestrogen receptor (alpha and beta) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 2001; 7: 1085-91.
26. Shime H, Kariya M, Orii A, et al. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21 (waf 1) and p53. J Clin Endocrinol Metab 2002; 87: 5610-7.
27. Hoffman PJ, Milliken DB, Gregg LC, et al. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004; 82:639-49.
28. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3: 167-70.
29. Liu P, Ramachandran S, AH Seyed M, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66:4011-9.
30. Pramoonjago P, Baras AS, MoskalukCA. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 2006; 25: 5626-39.
31. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006; 66: 3434-42.
32. Vialle-Castellano A, Gaugler B, Monty M, et al. Abundant expression of fibronectin is a major feature of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 2004; 18: 426-33.
33. Wasenius VM, Hemmer S, Kettunen E, et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-l, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003; 9: 68-75.
34. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-35.
35. Nakayama T, Inaba M, Naito S, et al. Expression of Angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma. World J Gastroenterol 2007; 13: 4473-9.
36. Shaoul R, Eliahu L, Sher I, et al. Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 2006; 350: 825-33.
37. Pekonen F, Nyman T, Rutanen EM. Differential expression of keratinocyte growth factor and its receptor in the human uterus. Mol Cell Endocrinol 1993; 95: 43-9.
38. Swisshelm K, MacekR, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev 2005; 57: 919-28.
39. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
40. Morohashi S, Kusumi T, Sato F, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 2007; 20: 139-43.
41. Takés AM, Kulka J, Paku S, et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005; 7: R296-305.
42. Gröne J, Weber B, Staub E, et al. Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12. Int J Colorectal Dis 2007; 22: 651-9.